Introduction
Hereditary tyrosinemia type I (McKusick 27670) is caused by a severe deficiency of fumarylacetoacetase (FAH)' (E.C. 3.7.1.2), the last enzyme in tyrosine degradation. The disorder is of autosomal recessive inheritance and is characterized by hypophosphatemic rickets due to renal tubular dysfunction and progressive liver disease with pronounced regeneration. It often leads to development of hepatocellular carcinoma if the patients survive for some years (1) . The disorder occurs worldwide but with particular high frequency in Quebec, Canada.
Recently we reported a mosaic pattern of immunoreactive FAH protein in liver tissue of five Norwegian tyrosinemia patients, and in two of the patients some areas of liver tissue contained up to 50% residual FAH activity (2) . We have now extended this investigation to 19 tyrosinemia patients of various ethnic origins. We furthermore report the results of mutation analysis of liver tissue from areas with or without immunoreactive FAH protein in four patients exhibiting the FAH mosaicism in liver tissue. In these patients the "reappearance" of immunoreactive FAH protein appeared to be caused by a reversion of the primary point mutation to the normal nucleotide in one of the alleles.
Methods
Patients. 18 compound heterozygous for the IVS 12 g +5-a mutation and a G '"-T nonsense mutation (E357X) (4) . Patient 3, transplanted at age 10 due to hepatocellular carcinoma, was homozygous for G "30-A, a combined splice and missense mutation (G337S) (3), and patient 4, transplanted at age 3 without cancer, was homozygous for G "2-T, a splice site mutation (5) .
Immunohistochemistry and mutation analysis in liver sections. Fig. 1 shows the immunohistochemical staining and the result of mutation analysis in patient 1. (Fig. 1 C, area b) (lane 4). In the latter, only a very small fraction of the PCR product is digested. Sequencing data of the PCR products from a normal control (Fig. 2 A) , the immunonegative liver tissue (Fig. 2 B) and the immunopositive liver tissue (Fig. 2 C) of patient 1, support a substantial shift from the mutated A, for which the patient was heterozygous, to a normal G nucleotide in the immunopositive liver tissue.
The results of patient 2, are given in Fig. 3 . Liver tissue from an immunonegative (Fig. 3 B, area a) and an immunopositive (area b) area was analyzed for the two mutations in this patient. Fig. 3 C shows restriction digestion by Asp700 of the PCR product surrounding the IVS 12g '5--a mutation from fibroblast extracts of a normal control (lane 1) and the patient (lane 2) and from the immunonegative liver tissue (Fig. 3 B , area a) (lane 3) and immunopositive liver tissue (Fig. 3 B, Restriction digestion by Pvufl of the 298-bp product (Fig. 4 C) showed no digestion of control fibroblasts (lane 1) and complete digestion of the product from the patient's fibroblasts (lane 2) and from the immunonegative liver tissue (Fig. 4 (Fig. 6) , who is homozygous for the G'92-+T mutation, restriction analysis (Fig. 6 C) again indicates a reversion of the mutation in one allele in the immunopositive liver tissue (Fig. 6 B, area b) (lane 4), in contrast to homozygosity for the mutation, with complete digestion, in the immunonegative tissue (Fig. 6 B, area a) (lane 3) and in fibroblasts (lane 2) from the patient.
In all patients the results were reproduced in 3-6 liver sections of the respective areas.
Discussion
Some problems adhered to the mutation analysis of the formalinfixed liver sections. The obtainable length of the PCR product varied considerably from one paraffin block to another. Presumably, the tissue fixation or other factors may have degraded the DNA considerably and in some blocks only very short PCR products could be amplified. Furthermore, routine tissue preparation is performed without precautions for DNA contamination. Careful precautions in preparation of the tissue sections had to be observed to avoid interfering DNA contamination. In Fig. 4 C and 6 C (lanes 3) representing immunonegative liver tissue from the patients, trace amounts of undigested PCR product, not containing the mutation, are visible. This could be due to unavoidable contamination of normal DNA derived either from the positive area in the same liver section or, more likely, from other sources. In patients 1 and 2, the immunopositive tissue did not show a complete reversion of the mutation, as visualized by weak bands of 73 and 36 bp (Fig. 1 D and 3 C, lanes 4 ). This could also be due to DNA contamination, but might as well be caused by (tissue) contribution of nuclei from non-hepatocyte cells which have retained the mutation. (Fig. B, area a) ; lane 4, immunopositive liver tissue (Fig. B, area b) .
A mosaic pattern of FAH activity and immunoreactive protein appears to be common in liver tissue from tyrosinemia patients as 16 of 19 patients of various ethnic origins showed the phenomenon. The patients investigated represent a selected group since they were all liver transplanted and none of the patients were transplanted in early infancy. The youngest patient (Fig. 4 B, area a) (Fig. 4 B, area b) with mosaicism, however, was 11 months, and the two patients from whom 8-12 liver blocks were investigated and no mosaicism found, were 5 and 10 years old. An age related ascertainment bias may therefore not be the sole explanation of the high incidence of FAH mosaicism.
In the immunopositive nodules investigated in the four patients subjected to mutation analysis, the mosaicism apparently was caused by a reversion of the primary point mutation in one allele. Alternative explanations may, however, account for the phenomenon in non-investigated nodules of the four patients and in other patients exhibiting the phenomenon. A second site mutation somewhere in the exons inducing conformational changes stabilizing the transcript or protein sufficiently to give immunoreactivity, and possibly enzyme activity, may explain the mosaic pattern of FAH protein. Second-site mutation in the codon of the primary defect may also, in certain cases, establish a codon for the correct amino acid.
In the compound heterozygote patient the same mutation was reverted to wild type in all four nodules investigated. This could be accidental due to the low number of nodules investigated. On the other hand, mutation liability is sequence dependent (6, 7), thus one of the mutations may revert more easily than the other. A gene conversion event or mitotic recombination between homologous chromosomes could theoretically explain the appearance of a normal allele in the compound heterozygote patient. Two of the patients with reverted mutations, however, were homozygous for their mutations, and no pseudogenes for FAH, for contribution of wild-type sequences, are known. Also, an early embryonic mutation with selective growth of the mutated cells may account for the mosaicism, but a high incidence of such an event would indicate a precipitating factor. As liver failure and thereby influence the course of the disorder. If the reversion of the genetic defect in tyrosinemia results mainly from accelerated cell regeneration such an event may not be exclusive to tyrosinemia and should be sought for in other genetic diseases in tissues with an induced, or natural high, rate of cell replication. The reversion of the disease causing point mutations in tyrosinemia, with the potential of self-induced cure, may be the counterpart to the carcinogenesis of the disorder, possibly reflecting the same process.
